What Do You Know Wednesday graphic
Medication Related: Osteonecrosis of the Jaw (MRONJ) and
the Relation with Denosumab
 
 
Learning objectives:

  • Explain the mechanism of action of denosumab and its effects on bone metabolism.

  • Recognize risk factors and clinical presentation of medication-related osteonecrosis of the jaw (MRONJ).

  • Identify preventive strategies and management approaches for patients receiving denosumab who develop MRONJ.

 
Instructions:
Please select the single best answer for each question. This quiz has 20 multiple choice questions. Answering 17 or more questions correctly will generate a certificate of completion for this quiz that we invite you to share on social media. Tag @iaomscommunications on Instagram.
 
Everyone who completes the quiz and submits their email will receive an email with their answer summary (correct and incorrect answers) and a specialized listing of IAOMS webinars to brush up on related skills. Most IAOMS webinars in our e-Learning Library are FREE for IAOMS Members. Not a member? Find out more!
 
Thank you and good luck!

What is the primary mechanism of action of denosumab?
Inhibition of osteoclast activity
Stimulation of osteoblast activity
Inhibition of angiogenesis
Stimulation of bone marrow production
Which receptor does denosumab target to exert its effects?
RANKL
VEGF
EGFR
PDGF
What is the most common clinical presentation of MRONJ associated with denosumab?
Pain and swelling in the jaw
Tooth mobility
Exposed necrotic bone
Facial asymmetry
. Which of the following is a known risk factor for developing MRONJ in patients treated with denosumab?
Smoking
Diabetes
Recent dental extraction
All of the above
What is the recommended initial management for a patient with early-stage MRONJ associated with denosumab?
Surgical resection
Antibiotic therapy and oral rinses
Discontinuation of denosumab
Radiation therapy
How often should patients receiving denosumab be monitored for signs of MRONJ?
Every 3 months
Every 6 months
Annually
Only if symptoms develop
What is the role of conservative therapy in the management of MRONJ associated with denosumab?
To delay the need for surgical intervention
To completely cure the condition
To prevent the development of MRONJ
To reduce the dosage of denosumab
Which imaging modality is most useful for diagnosing MRONJ in patients treated with denosumab?
Panoramic radiograph
Computed tomography (CT)
Magnetic resonance imaging (MRI)
Ultrasonography
What is the recommended duration of antibiotic therapy for patients with MRONJ associated with denosumab?
1 week
2 weeks
4-6 weeks
8-12 weeks
Which of the following is NOT a recommended preventive measure for MRONJ in patients starting denosumab therapy?
Dental examination and treatment of existing dental issues
Use of high-dose vitamin D supplements
Patient education on oral hygiene
Avoidance of invasive dental procedures
What is the primary goal of surgical intervention in advanced cases of MRONJ associated with denosumab?
Complete removal of necrotic bone
Pain management
Restoration of jaw function
Prevention of infection
Which of the following is a potential complication of MRONJ surgery in patients treated with denosumab?
Delayed wound healing
Increased risk of infection
Recurrence of osteonecrosis
All of the above
What is the role of hyperbaric oxygen therapy in the management of MRONJ associated with denosumab?
It is the first-line treatment
It is used as an adjunctive therapy
It is not recommended
It is used only in refractory cases
Which patient population is at higher risk for developing MRONJ when treated with denosumab?
Postmenopausal women with osteoporosis
Patients with metastatic bone disease
Young adults with rheumatoid arthritis
Children with osteogenesis imperfecta
What is the recommended follow-up protocol for patients who have undergone surgical resection for MRONJ associated with denosumab?
Monthly follow-up for the first 6 months
Biannual follow-up for the first year
Annual follow-up indefinitely
Follow-up only if symptoms recur
Which of the following is a key factor in the pathogenesis of MRONJ associated with denosumab?
Inhibition of bone resorption
Increased bone formation
Enhanced angiogenesis
Stimulation of immune response
What is the typical duration of denosumab therapy before the onset of MRONJ symptoms?
1-3 months
6-12 months
1-2 years
Over 2 years
Which of the following is a common site for MRONJ development in patients treated with denosumab?
Maxilla
Mandible
Zygomatic bone
Nasal bone
What is the role of patient education in the prevention of MRONJ associated with denosumab?
It is not necessary
It is only for high-risk patients
It is essential for all patients
It is optional
Which of the following is a recommended strategy to minimize the risk of MRONJ in patients receiving denosumab?
Regular dental check-ups
Maintaining good oral hygiene
Avoiding invasive dental procedures
All of the above
Name (First and Last name as you would like it to appear on your certificate, if you get 17 out of 20 correct answers):
{"name":"Complications of Zygomatic Implants Learning objectives:- Recognize early and late complications associated with zygomatic implants. - Interpret clinical and radiographic findings relevant to diagnosis. - Select evidence‑based strategies for prevention an", "url":"https://www.quiz-maker.com/QG7VGPMBI","emurl":1,"txt":"What is the primary mechanism of action of denosumab?, Which receptor does denosumab target to exert its effects?, What is the most common clinical presentation of MRONJ associated with denosumab?","img":"https://www.quiz-maker.com/3012/images/ogquiz.png","accounts":"@iaomscommunications","hash":"#IAOMS, #OMFS #OralSurgery #Craniofacial #Maxollofacial #HeadandKneck"}